16 Result(s)

Article

Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib

Circulating tumor DNA (ctDNA) provides molecular information on tumor heterogeneity. The prognostic usefulness of ctDNA after first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) a...

Ou Yamaguchi, Norimitsu Kasahara, Hiroshi Soda, Hisao Imai… in Scientific Reports (2023)

Article

Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancer

To compare different response criteria using computed tomography (CT) and positron emission tomography (PET) in measuring response and survival in the early phase after programmed death-1 (PD-1) blockade monot...

Kyoichi Kaira, Ou Yamaguchi, Ichiro Naruse, Yukihiro Umeda, Takeshi Honda… in Cancer Imaging (2023)

Article

Prognostic significance of tumor infiltrating lymphocytes on first-line pembrolizumab efficacy in advanced non-small cell lung cancer

Tumor-infiltrating lymphocytes (TILs) in the tumor and stroma are expected to accurately predict the efficacy of programmed death-1 (PD-1) blockade therapy. However, little is known about the prognostic signif...

Kyoichi Kaira, Ou Yamaguchi, Tomonori Kawasaki, Kousuke Hashimoto… in Discover Oncology (2023)

Article

Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer

This study examined the activity and safety of amrubicin monotherapy among relapsed small-cell lung cancer (SCLC) patients who had previously been treated with atezolizumab plus carboplatin and etoposide (AteC...

Hisao Imai, Yoshiaki Nagai, Hiroyuki Minemura, Takeshi Tsuda… in Investigational New Drugs (2022)

Article

Prospective assessment using ¹⁸F-FDG PET/CT as a novel predictor for early response to PD-1 blockade in non-small-cell lung cancer

Anti-programmed death-1 (PD-1) blockade is a standard treatment for advanced non-small-cell lung cancer (NSCLC). However, no appropriate modality exists for monitoring its therapeutic response immediately afte...

Ou Yamaguchi, Kyoichi Kaira, Ichiro Naruse, Yukihiro Umeda… in Scientific Reports (2022)

Article

Correction to: Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B)

Yukari Tsubata, Kana Watanabe, Ryota Saito… in International Journal of Clinical Oncology (2022)

Article

Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B)

Osimertinib is effective in patients with T790M mutation-positive advanced non-small-cell lung cancer (NSCLC) resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). However, it...

Yukari Tsubata, Kana Watanabe, Ryota Saito… in International Journal of Clinical Oncology (2022)

Article

A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress)

Durvalumab is a standard drug used during maintenance therapy after chemoradiotherapy in patients with locally advanced non-small cell lung cancer (LA-NSCLC). However, little is known about the clinical benefi...

Kyoichi Kaira, Atsuto Mouri, Shingo Kato, Kenichi Yoshimura, Hiroshi Kagamu… in BMC Cancer (2020)

Article

Tumor metabolic volume by ¹⁸F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%

There is a lack of markers for predicting favorable outcomes after pembrolizumab therapy in patients with non-small cell lung cancer (NSCLC) with programmed death ligand-1 (PD-L1) expression ≥ 50%. This retros...

Ou Yamaguchi, Kyoichi Kaira, Kosuke Hashimoto, Atsuto Mouri… in Scientific Reports (2020)

Article

Correction to: Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation

In the original publication of the article, the authors found few errors and the corrections are given below:

Ou Yamaguchi, Kyoichi Kaira, Atsuto Mouri… in Cancer Chemotherapy and Pharmacology (2020)

Article

Multiple tuberculous nodules with metachronous changes: a case report

Spontaneous regression of lesions occurs in non-infectious benign diseases, such as sarcoidosis, as well as in infectious diseases, such as tuberculosis. Lung cancer and malignant lymphoma, on the other hand, ...

Munehisa Fukusumi, Tatsuya Ibe, Shinjiro Takeoka, Kazushige Wakuda… in BMC Research Notes (2013)

Article

Better efficacy of S-1 treatment for thymic carcinoma: case report and review of the literature

Primary thymic carcinoma is a rare tumor of the thymus gland. The role of chemotherapy in treating advanced thymic carcinoma is unclear. It has recently been reported that thymidylate synthase (TS), dihydropyr...

Yoichiro Hamamoto, Tatsuya Ibe, Kazushige Wakuda… in International Cancer Conference Journal (2013)